Señales en vivo de SPRB | Maximiza tus Ganancias con Getagraph.com

VENDER 113258 min ago

@ $4.51

Emitido: 13 feb 2024 @ 15:35

Retorno: -84.09%

Señal anterior: feb 13 - 09:31

Señal anterior: Comprar

Retorno: 4.64 %

Live Chart Being Loaded With Signals

Commentary (1 may 2024 @ 16:00):

Stats
Volumen de hoy	747 686
Volumen promedio	1.38M
Capitalización de mercado	29.52M
EPS	$0 ( 2024-03-21 )
Próxima fecha de ganancias	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0.00300 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Novo Holdings A/s	Sell	465 021	COMMON STOCK
2024-03-18	Novo Holdings A/s	Sell	842 020	COMMON STOCK
2024-03-19	Novo Holdings A/s	Sell	593 000	COMMON STOCK
2024-03-20	Novo Holdings A/s	Sell	359 979	COMMON STOCK
2024-03-14	Novo Holdings A/s	Sell	1 912 316	COMMON STOCK

INSIDER POWER
2.52
Last 98 transactions
Buy: 11 294 782 \| Sell: 4 967 660

Volumen Correlación

Largo: 0.08 (neutral)

Corto: 0.26 (neutral)

Signal:(43.972) Neutral

Spruce Biosciences, Inc. Correlación

10 Correlaciones Más Positivas
DYNT	0.967
DGLY	0.954
FTFT	0.94
SLNO	0.94
SYKE	0.929
CVV	0.927
LIVE	0.925
CSWI	0.923
FELE	0.922
IPHA	0.921

10 Correlaciones Más Negativas
MTEX	-0.906
LCAP	-0.905
AHPI	-0.899
NAKD	-0.887
PROC	-0.883
LAWS	-0.88
VERA	-0.872
GRPH	-0.869
OP	-0.868
TRIT	-0.868

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Spruce Biosciences, Inc. Correlación - Moneda/Commodity

-0.46
( neutral )

-0.39
( neutral )

0.00
( neutral )

0.51
( weak )

Spruce Biosciences, Inc. Finanzas

Annual	2023
Ingresos:	$10.09M
Beneficio Bruto:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2023
Ingresos:	$10.09M
Beneficio Bruto:	$10.02M (99.31 %)
EPS:	$-1.240

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-429 000 (0.00 %)
EPS:	$-1.920

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.813

Financial Reports:

No articles found.

Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.